

AMENDMENTS TO THE CLAIMS

This listing of the claims replaces all prior versions and listings:

1. (currently amended): A method for generating an immune response against one or more intracellular pathogens within warm-blooded animals, comprising:

(a) administering to a warm-blooded animal a gene delivery vehicle comprising a polynucleotide encoding at least one immunogenic portion of an antigen obtained from an intracellular pathogen, wherein the gene delivery vehicle is selected from the group consisting of retroviral vectors, alphavirus vectors, parvovirus vectors, plasmid vectors, or eukaryotic layered vector initiation system vectors; and

(b) administering to said warm-blooded animal, prior to or subsequent to administration of said gene delivery vehicle, at least one protein which comprises at least one immunogenic portion of an antigen obtained from said intracellular pathogen, such that an immune response against the intracellular pathogen is generated.

2. (original): The method according to claim 1, further comprising the step of administering an immunomodulatory cofactor.

3. (previously presented): The method according to claim 1, wherein said protein is administered prior to administration of said gene delivery vehicle.

4. (original): The method according to claim 1, wherein said intracellular pathogen is virus and said antigen a viral antigen.

5. (previously presented): The method according to claim 4, wherein said virus is a hepatitis virus.

6 to 11. (canceled).

12. (previously presented): The method according to claim 1, wherein said gene delivery vehicle is an alphavirus vector.

13. (previously presented): The method according to claim 1, wherein said gene delivery vehicle is a eukaryotic layered vector initiation system vector.

14 to 23. (canceled).

24. (previously presented): The method of claim 1, wherein the gene delivery vehicle comprises naked DNA.

25. (canceled).

26. (previously presented): The method according to claim 4, wherein said virus is a feline immunodeficiency virus (FIV) or a human immunodeficiency virus (HIV).

27. (previously presented): The method according to claim 1, wherein said gene delivery vehicle is a retroviral vector.

28. (previously presented): The method according to claim 1, wherein said gene delivery vehicle is a parvovirus vector.

29. (previously presented): The method according to claim 28, wherein said gene delivery vehicle is an adeno-associated virus vector.

30. (previously presented): The method according to claim 1, wherein said gene delivery vehicle is a plasmid vector.